Low-density lipoprotein size and lipoproteinassociated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir

Antiviral Therapy

Volumn 16, Issue 4, 2011, Pages 459-468

  Saumoy, Maria ^a   Ordoñez Llanos, Jordi ^b,c   Martínez, Esteban ^d   Barragán, Patricia ^a   Ribera, Esteban ^a   Bonet, Rosa ^b,c   Knobel, Hernando ^e   Negredo, Eugenia ^f   Loncá, Montserrat ^d   Curran, Adrian ^a   Gatell, Josep Maria ^d   Podzamczer, Daniel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Hospital Sant Pau   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PHOSPHOLIPASE A2; PROTEINASE INHIBITOR; STAVUDINE; STAVUDINE PLUS ZIDOVUDINE; THYMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WAIST HIP RATIO;

ADENINE; ADULT; ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL PROTOCOLS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PHOSPHOLIPASES A2; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79959399010     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1785     Document Type: Article

References (37)

1. Kamin DS, Grinspoon S. Cardiovascular disease in HIVpositive patients. AIDS 2005; 19:641-652.
2. Aberg JA. Cardiovascular complications in HIV management: past, present and future. J Acquir Immune Defic Syndr 2009; 50:54-64.
3. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis 2010; 201:318-330.
4. The SMART/INSIGHT and the D:A:D study groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-F24.
5. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine a randomized, 96-week, trial. Clin Infect Dis 2009; 49:1591-1601.
6. Moyle GJ, Sabin CA, Cartledge J, et al. RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20:2043-2050.
7. Martínez E, Arranz JA, Podzamczer D, et al. Bicombo Study Team. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009; 51:290-297.
8. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
9. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547-1556.
10. Virgili N, Fisac C, Martínez E, Ribera E, Gatell JM, Podzamczer D. Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. J Acquir Immune Defic Syndr 2009; 50:552-553.
11. Satchell C, O'Connor E, Peace A, et al. Platelet hyperreactivity in HIV-1 infected patients on abacavir-containing ART. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 151LB.
12. McComsey G, Smith K, Patel P, et al. Similar reductions in markers of inflammation and endothelial activation of abacavir/lamivudine or tenofovir/emtricitabine: the HEAT study. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 732.
13. Palella FJ, Gange S, Elion R, et al. Inflammatory biomarkers and abacavir use in the Women's Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010; 24:1657-1665.
14. Martinez E, Larrousse M, Podzamczer D, et al. Abacavirbased therapy does not affect biological mechanisms associated with cardiovascular dysfunction. AIDS 2010; 24:F1-F9.
15. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99:1-14. (Pubitemid 43124966)
16. Gazi IF, Tsimihodimos V, Tselepis AD, Elisaf M, Mikhailidis DP. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7:53-72. (Pubitemid 46091576)
17. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007; 82:159-165. (Pubitemid 46198473)
18. Noto H, Hara M, Karasawa K, et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23:829-835. (Pubitemid 36566173)
19. Negredo E, Ribalta J, Paredes R, et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002; 16:1383-1389. (Pubitemid 34722070)
20. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003; 168:107-113.
21. Riddler SA, Li X, Otvos J, et al. Antiretroviral therapy is associated with and atherogenic lipoprotein phenotype among HIV-1-infected men in the multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr doi:10.1097/ QAI.0b013e31817bbbf0
22. Duprez DA, Kuller LH, Tracy R, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
23. National Cholesterol Education Program. Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation 2002; 106:3143-3421.
24. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847. (Pubitemid 28213628)
25. Hoefner DM, Hodel SD, O'Brien JF, et al. Development of a rapid, quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL System. Clin Chem 2001; 47:266-274. (Pubitemid 32142925)
26. Benítez S, Sánchez-Quesada JL, Ribas V, et al. Plateletactivating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction. Circulation 2003; 108:92-96. (Pubitemid 36859026)
27. Hodges JR, Lehmann EL. Confidence interval for the difference between two medians by Hodges-Lehmann method: 'Estimates of location based on rank tests'. Ann Math Statist 1963; 34:598-611.
28. Benson C, Ribaudo H, Zheng E, et al. No association of abacavir use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, Canada. Abstract 721
29. Bedimo R, Westfall A, Drechsler H, et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 18-22 July 2009, Cape Town, South Africa. Abstract MOAB202.
30. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a casecontrol study nested within the french hospital datebase on HIV ANRS Cohort CO4. Arch Intern Med 2010; 170:1228-1238.
31. Behrens GM, Reiss P. Abacavir and cardiovascular risk. Curr Opin Infect Dis 2010; 23:9-14.
32. Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab 2003; 88:4525-4532. (Pubitemid 37357487)
33. Furnkranz A, Schober A, Bochkov VN, et al. Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb Vasc Biol 2005; 25:633-638. (Pubitemid 40315690)
34. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992; 95:69-76.
35. Tellis CC, Tselepis AD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta 2009; 1791:327-338.
36. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. The epidemiology of Lp-PLA2: distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 2007; 190:388-396. (Pubitemid 46074030)
37. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101:41F-50F.